- Home
- ODD vs HAE Comparison
ODD vs HAE Comparison
Compare ODD & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- HAE
- Stock Information
- Founded
- ODD 2018
- HAE 1971
- Country
- ODD Israel
- HAE United States
- Employees
- ODD N/A
- HAE N/A
- Industry
- ODD
- HAE Medical/Dental Instruments
- Sector
- ODD
- HAE Health Care
- Exchange
- ODD Nasdaq
- HAE Nasdaq
- Market Cap
- ODD 3.8B
- HAE 3.3B
- IPO Year
- ODD 2023
- HAE 1991
- Fundamental
- Price
- ODD $71.72
- HAE $71.13
- Analyst Decision
- ODD Buy
- HAE Strong Buy
- Analyst Count
- ODD 8
- HAE 9
- Target Price
- ODD $59.00
- HAE $99.78
- AVG Volume (30 Days)
- ODD 1.2M
- HAE 505.1K
- Earning Date
- ODD 08-06-2025
- HAE 08-07-2025
- Dividend Yield
- ODD N/A
- HAE N/A
- EPS Growth
- ODD 45.36
- HAE 44.54
- EPS
- ODD 1.74
- HAE 3.31
- Revenue
- ODD $703,488,000.00
- HAE $1,360,824,000.00
- Revenue This Year
- ODD $24.46
- HAE N/A
- Revenue Next Year
- ODD $20.26
- HAE $7.18
- P/E Ratio
- ODD $41.30
- HAE $21.49
- Revenue Growth
- ODD 26.83
- HAE 3.96
- 52 Week Low
- ODD $32.71
- HAE $55.30
- 52 Week High
- ODD $79.18
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- ODD 55.62
- HAE 60.48
- Support Level
- ODD $69.63
- HAE $68.62
- Resistance Level
- ODD $74.50
- HAE $73.78
- Average True Range (ATR)
- ODD 2.65
- HAE 1.53
- MACD
- ODD -1.15
- HAE -0.20
- Stochastic Oscillator
- ODD 25.84
- HAE 60.51
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.